First-line PARP inhibitor maintenance after platinum chemotherapy reduces progression risk in certain patients with ovarian cancer but increases the risk for serious toxicity.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/do-parp-inhibitors-benefit-patients-ovarian-cancer-2025a1000xa6?src=rss
Author :
Publish date : 2025-11-28 05:16:00
Copyright for syndicated content belongs to the linked Source.
